The procedure was performed as part of NeoVista’s Cabernet trial, which seeks to enroll a total of 450 patients (300 in the radiation treatment arm) in approximately 40 sites worldwide to evaluate the efficacy and safety of NeoVista’s novel radiation therapy. Patients in the study receive a single treatment with NeoVista’s targeted radiation in combination with an injection of Lucentis at the time of radiation delivery to maximize immediate effect.
Unlike the current standard of care which requires costly monthly eye injections, NeoVista’s investigational therapy delivers a one-time dose of radiation providing a less invasive and potentially more cost-effective treatment option.
In addition to Germany, locations of Cabernet study sites include the UK, Spain, Switzerland, Austria, Israel, Brazil, Mexico, Peru, and the US. The Cabernet study is intended to support eventual filing for regulatory approval to market the product worldwide.
John Hendrick, president and CEO of NeoVista, said: “Ultimately, our goal is to restore vision and quality of life to elderly patients who have been stricken with this debilitating disease by liberating them of the burdens associated with existing wet AMD therapies.”